Introduction
Myocardial infarction, peripheral arterial disease, and stroke are highly morbid and mortal conditions [1] that are consequent to the progression of atherosclerotic plaque lesions in the intimal component of vascular wall. Atherosclerosis silently develops over decades of life from sub-endothelial fatty streaks deposition into established lesions compromising blood flow in the arterial vessel that may rupture causing an acute luminal occlusion and organ ischemia [2] . In spite of the higher prevalence reported in modern industrialized societies [1] , atherosclerosis has impacted human health for centuries as evidenced by the recent documentation of lesions in ancient Egyptian mummies [3] .
Clinical, pathologic, and experimental observations have fueled the current zeitgeist that atherosclerosis is a chronic inflammatory disease state. This central feature of atherosclerosis is under enormous investigative efforts to dissect the proand anti-inflammatory cellular and molecular mechanisms governing disease development [4] . A number of cellular pathways have been implicated in modulating this pathologic inflammatory process [5] . Studies utilizing high throughput technologies coupled with enormous advances in our understanding of the human genome have led to the discovery of many atheroregulatory candidates. Amongst the most exciting developments of the past decade has been the identification of a family of transcriptional regulators termed Kruppel-like Factors (KLFs) as athero-protective factors [6] . Indeed, studies from our group and others have demonstrated the key role of this family of transcription factors (KLFs) in governing cell activation and inflammatory responses in many cellular components of the vascular wall and plaque lesion. The nomenclature of KLFs came from the German word kruppel (for "cripple"), a protein first described in Drosophila [7] . Embryos with mutated kruppel had a lethal developmental defect in body patterning and a "crippling" appearance. In 1993, the first mammalian homolog to kruppel was identified in red blood cell lineage, therefore named erythroid Kruppel-like factor (EKLF/KLF-1) [8] . Over the last two decades, a total of 17 members were identified in mammalians constituting a large family of KLFs that broadly regulate numerous physiological and pathological processes in many cell types and organ systems [.9 ], from fetal development to circadian regulation of cardiac repolarization [10, 11] . KLFs represent a subgroup of the zinc finger family of DNA-binding transcription factors, and they are distinguished by several features: i) three Cysteine2/Histidine2 containing zinc fingers located at the extreme C-terminus of the protein, ii) a highly conserved seven residue sequence between zinc fingers, TGEKP(Y/F)X, and iii) DNA-binding to specific sequences such as the "CACCC" sequence or the "GT box" [12] [13] [14] . The highly divergent non-DNA-binding regions mediate protein-protein interactions, and modulate transactivation and transrepression.
In this review we summarize the emerging role of certain members of the KLF transcription factors in the endothelial, smooth muscle, and immune cells biology with a focus on inflammation and implications for atherosclerosis (summarized in Table 1 ). • Anti-inflammatory and anti-thrombotic (induces eNOS, thrombomodulin; inhibits cytokine-mediated expression of VECAM-1 and Eselectin; inhibits thrombin-mediated induction of monocyte chemotactic protein 1, IL-6, and IL-8).
↓ by turbulent flow, inflammatory cytokines, oxidative stress, miR-92a • Maintains endothelial barrier integrity (induces expression of occludin and modification of a signaling molecule myosin light chain).
• Anti-angiogenic (inhibitor of HIF-1α expression and function; decreases VEGFR2).
• Controls SMCs phenotype (by inducing release of vesicles enriched with miR-143/145 cluster from ECs).
KLF4
↑ by laminar flow, statins • Anti-inflammatory and anti-thrombotic (induces eNOS and TM, and reduces expression of VCAM-1, and E-selectin).
↓ by miR-92a
• Promotes a normal endothelial barrier function by inducing the transcription of VE-cadherin KLF6 ↑ by vascular injury • Promotes vascular remodeling (Interacts with SP1 and activates endoglin, collagen α1 (I), TGF-β 1 , and TGF-β receptor type I).
• Induces endothelial cell migration by causing the disruption of an SP2/KLF6 repression complex on the matrix metalloproteinase-9 promoter via SHP (small heterodimeric partner) after Farnesoid X Receptor activation.
KLF15
• Endothelial cell sprouting and migration (activates the bone morphogenetic proteins (BMP) endothelial cell precursor-derived regulator (BMPER)).
VSMC KLF4
• Critical for SMC phenotypic switching. Atherogenic stimuli repressed SMC-marker gene expression through KLF4-dependent conserved G/C Repressor elements.
KLF5
• Major regulator for vascular development and remodeling.
KLF15
• Level is induced in response to in vivo and in vitro vascular injury, and in atherosclerotic lesions.
• Potentially has proatherogenic role by activating PDGF-A, cyclin D1, cyclin B, Egr-1, VEGF and PAI-1 and subsequently promoting SMC proliferation, migration, apoptosis and vascular inflammation.
• Expression in the vessel wall is largely in SMC.
• Vascular KLF15 mRNA expression is significantly decreased by pathogenic stimuli, i.e., PDGF-BB, Angiotensin II and vascular injury both in rodent and in human vascular disease models.
• Systematic KLF15-deficiency promoted the development of restenosis and aortic aneurysm formation.
• KLF15-deficiency increases SMC proliferation, migration and cell death, enhances p53 function, decreases angiogenesis in vasa vasorum and promote vascular inflammation.
Macrophages/ Monocytes

KLF2
↑ by Statins • Anti-inflammatory (attenuates LPS-mediated inflammatory cytokines production).
↓ by LPS, hypoxia • Myeloid specific deletion of KLF2 exhibited elevated baseline plasma levels of pro-inflammatory molecules (such as IL1b, IL12, INFg, MIP1b, MIP1a, and TNFa). Animals with KLF2 myeloid deletion had robust capacity to combat polymicrobial infections
• Inhibits macrophage lipid uptake by regulating the lipid binding protein FABP4.
• Inhibits NFkB/HIF-1a axis, a central regulator of macrophage pro-inflammatory activation (inhibits recruitment of NFkB coactivators p300 and PCAF).
• Myeloid deletion of KLF2 results in augmented atherosclerosis.
• Myeloid KLF2 level is reduced in human subjects with sepsis and atherosclerosis.
KLF4
↑ by IL4
• Regulates monopoiesis (is a gene target of PU1) and macrophage subset specification (required for both Ly6Chi and Ly6Clo monocyte populations).
↓ by LPS
• Regulates macrophage polarization (cooperate with STAT6 to promote M2 targets, inhibits M1 phenotype via inhibition of NF-KB transcriptional activity by sequestration of the critical coactivators p300 and PCAF).
• KLF4 -/-macrophages exhibited enhanced bactericidal effects, and animals with myeloid-specific deletion of KLF4 exhibited delayed wound healing, increased insulin resistance, and diet-induced obesity • Required for mature single-positive (SP) CD4+ and CD8+ T cells trafficking and migration [promotes expression of sphingosine 1-phosphate receptor 1 (S1PR1). Thymocytes deficient in KLF2 have attenuated expression of surface receptors (S1PR1, L-selectin, CCR7, and integrin β7).
• KLF2 -/-T cells express proinflammatory chemokine receptors found on memory cells and activated thymocytes (CXCR3, CCR3, CCR5 and CD69).
• Retroviral KLF2 overexpression and statin treatment resulted in an anti-inflammatory phenotype in a mouse-model of myocarditis with attenuation of T-cell proliferation and interferon-γ (IFN-γ) expression.
KLF3
• Rapidly downregulated upon activation of B cells, suggesting a role in B cell quiescence.
• Expression is attenuated in the absence of KLF2 suggesting that KLF2 may promote expression of KLF3. The balanced expression of KLF2 and KLF3 influences B cell differentiation.
• Responsible for innate and humoral responses (CD 19+ splenic B cells of KLF 3 -/-mice have defects in TLR signaling pathway with significant downregulation of multiple TLRs and their coreceptor molecules).
• KLF3 deficient marginal B cells have an attenuated LPS response (mediated by the downregulation of Tlr6 and CD3).
KLF4
• Activates cyclin D2 expression by binding to the cyclin D2 promoter resulting in B cell receptor (BCR) -mediated B cell proliferation.
• Overexpression in B cells transformed by the ABL oncogene induces cell cycle arrest.
• Induce expression of p21Cip/Waf1 and downregulates c-Myc and cyclin D2 resulting in a differential anti-proliferative effect on B cells. .
• Rapidly degraded upon B cell activation.
• KLF 4-/-animals have decreased cellularity and reduced T-cell numbers in spleen.
• Promotes IL-17 expression and differentiation of Th17 cells (binds to IL-17 promoter independent of RORγt).
• Animals deficient in KLF4 show significant reduction in the severity of autoimmune encephalomyelitis characterized by reduced Th17 responses and infiltration of leukocytes into the central nervous system.
KLF10
• Regulates CD4+CD25-T cell activation, T regulatory cell differentiation and Treg cell suppressor function.
• Promotes TGFβ1 and Foxp3 expression in CD4+CD25-T cells.
• Treg cells deficient in KLF10 have reduced suppressor function due to decreased expression of TGFβ1.
• Adoptive transfer of KLF10 -/-CD4+CD25-T cells in ApoE-/-/scid mice accelerated atherosclerosis.
KLF13
• Phosphorylation of KLF13 by transcriptional co-activators promotes expression of the proinflammatory chemokine, RANTES to promote T cell activation.
• Mice deficient in KLF13 no longer inhibit expression of the anti-apoptotic factor BCL-XL and have enlarged thymuses and spleens containing preserved thymocytes.
Endothelial Cells
Endothelial cell dysfunction plays a central role in the development of vascular disease states such as atherosclerosis and thrombosis [15] . The endothelium consists of a single layer of cells that line the blood vessel lumen and therefore is uniquely positioned to transduce and integrate both biochemical (e.g., inflammatory cytokines) and biomechanical (e.g., shear stress) stimuli from the blood to the underlying blood vessel wall [16] (book chapter). Inflammatory cytokines and nonlaminar blood flow induce endothelial dysfunction and confer a pro-adhesive and pro-thrombotic phenotype. Accumulating evidence from our group and others shows that members of the KLF family critically regulate endothelial function and vascular homeostasis. Among the KLF family, KLF2, 4, and 6 have emerged as particularly important in endothelial biology.
KLF2
KLF2 is highly expressed in ECs and has been implicated as a "molecular switch" regulating endothelial function in health and disease (reviewed in Atkins and Jain [15] ). KLF2 is upregulated by laminar shear stress, as well as by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (i.e., statins), and inhibited by turbulent shear stress, inflammatory cytokines, and oxidative stress. In turn, KLF2 differentially regulates the expression of factors that confer anti-inflammatory, antithrombotic, and antiproliferative effects in endothelial cells. The expression of KLF2 can be modulated at multiple levels, including transcriptional, posttranscriptional via miR-92a, and posttranslational modifications [17] . KLF2 has been shown to be regulated by MEF2 and MEK5/ERK5/MEF2 flow pathway [15] and more recently identified AMPK/ERK5/MEF2 pathway [18] , thereby establishing a molecular link between flow and its downstream effects in endothelial cells. Our group was the first to establish KLF2 as an antiatherogenic factor in vivo, demonstrating that KLF2 hemizygous mice have increased plaque burden in the ApoE model of atherosclerosis. KLF2 strongly upregulates eNOS and thrombomodulin and inhibits cytokine mediated induction of cell adhesion molecules. KLF2 regulates endothelial inflammation by inhibiting expression of VCAM-1 and E-selectin in response to various proinflammatory cytokines, which correlated with decreased T cell attachment and rolling on endothelial monolayers [19] . KLF2 potently inhibits thrombin-mediated induction of multiple cytokines/chemokines (e.g., monocyte chemotactic protein 1, IL-6, and IL-8) by inhibiting expression of its principal receptor protease-activated receptor 1 [20] .
Recent studies provide evidence that KLF2 plays an essential role in maintaining endothelial barrier integrity via differential effects on the expression of key junction protein occludin and modification of a signaling molecule myosin light chain [21] .
Constitutive and endothelial-restricted KLF2
−/− mice die at embryonic day 10.5 owing to lack of vascular tone, bleeding and cardiac dysfunction secondary to vascular complications [22, 23] . KLF2 is an inhibitor of HIF-1α expression and function and, therefore, potent inhibitor of angiogenesis [24] . KLF2 is also a regulator of the key VEGF receptor VEGFR2 [25] . A recent exciting finding may provide a promising strategy to combat atherosclerosis. KLF2-transduced cells release vesicles with a selective enrichment of miR-143/145 that regulates SMC gene expression and provide an atheroprotective effect in endothelial cells [26] .
KLF4
A potential role for KLF4 in endothelial biology was first provided by Yet and colleagues, who cloned this factor from an endothelial cell library [27] . Subsequently, Hamik, and colleagues identified KLF4 as mechanosensitive factor induced by laminar flow [28] . The expression of KLF4 is also increased in the presence of simvastatin, lovastatin, and mevastatin, and this increase is dependent on ERK activation and confers vasoprotection [29] . KLF4 overexpression induces several antiinflammatory and antithrombotic factors such as eNOS and TM, whereas knockdown of KLF4 enhances TNFα-induced VCAM-1 and tissue factor expression [28] . Interestingly, KLF4 overexpression in ECs significantly reduced TNF-alpha-induced E-selectin [30] .
More recently, it was shown that KLF4 binds to the VEcadherin promoter in mature ECs and induces VE-cadherin transcription required for the maintenance of normal endothelial barrier function [31] .
In conclusion, KLF4 may play a central role in regulation of proliferation, inflammation, and differentiation.
KLF6
KLF6 is induced after vascular injury and is responsible for the transcriptional activation of several genes involved in vascular remodeling, including urokinase plasminogen activator, endoglin, collagen α1 (I), TGF-β 1 , and TGF-β receptor type I, and requires the participation and interaction between with Sp1 [9•]. In response to vascular injury, KLF6 interacts with Sp1 and cooperatively binds and transactivates the endoglin promoter [32] . Endoglin is an endothelial membrane glycoprotein involved in vascular remodeling and cardiovascular development that is up regulated in response to arterial injury.
KLF6 has been demonstrated to play a role in endothelial cell motility. Farnesoid X receptor activation leads to the disruption of an SP2/KLF6 repression complex on the matrix metalloproteinase-9 promoter via SHP (small heterodimeric partner). The resulting upregulation of matrix metalloproteinase-9 induces endothelial cell migration, a fundamental step in the process of vascular remodeling and repair [33] .
KLF15
KLF15 is a strong and direct activator of the bone morphogenetic proteins (BMP) endothelial cell precursor-derived regulator (BMPER), a novel extracellular BMP modulator that controls the effect of BMP4 on critical endothelial cell functions such as sprouting and migration [34] . BMPs are upregulated in athero-prone regions in blood vessels and may contribute to vascular calcification and the development of atherosclerotic plaques [35] .
Smooth Muscle Cells
Vascular intrinsic SMCs are a major cell content in atherosclerotic lesions [36, 37] . VSMCs exhibits significant plasticity, upon atherogenic stimuli they undergo phenotypic switching, i.e., smooth muscle differentiation marker genes repression [38, 39] , and increased proliferation and migration into neointimal layer. It has been proposed that some VSMCs may give rise to macrophage-or myeloidlike cells that may further contribute to plaque formation. However, this phenotypic switch is considered ambiguous and definitive in vivo evidence is currently lacking [40] . It is therefore crucially important to identify molecular mechanisms and transcriptional pathways that may modulate this process and govern VSMCs atherogenic effect. Three KLFs are currently known to be expressed in VSMCs and implicated in phenotypic switch and atherogenesis: KLF 4, 5 and 15.
KLF4
SMC phenotypic switching is characterized by the coordinate down-regulation of SMC markers including smooth muscle a-actin, SM22a and smooth muscle myosin heavy chain (SM-MHC) [4, [41] [42] [43] [44] . In SMC, KLF4 is known as a critical factor mediating SMC phenotypic switching. The Owens laboratory has provided strong evidence that atherogenic stimuli repressed SMC-marker gene expression through conserved G/C Repressor elements is KLF4 dependent [45] [46] [47] . This suggests that KLF4 may play a pro-atherosclerotic role in SMC based on the above reports.
However, KLF4 is a transcriptional factor with multifaceted functions. KLF4 is known as a critical factor in embryonic stem cell pluripotency maintenance [48] and somatic cells reprograming [49, 50] . Yang's Lab reported that KLF4-null MEFs are genetically unstable as evident by the presence of aneuploidy, chromosome aberration and centrosome amplification [51] . As SMC genetic mutation and chromosomal abnormalities are associated with atherosclerotic plaque formation, expansion and stability [52] [53] [54] , it is possible that SMC KLF4 may serve as an athroprotective factor in this perspective. In addition, KLF4 is implicated in keeping vascular heterogeneity and decreasing atherosusceptibility by its anti-inflammatory function in macrophage [55••] and endothelium cells [29, 56, 57] . In this regard, if the same mechanisms apply in SMC, KLF4 is also predicted to be atheroprotective. To date, definitive evidence regarding SMC KLF4's role in atherogenesis is lacking but is clearly of great interest.
KLF5
KLF5 is a major regulator for vascular development and remodeling. Vascular SMC KLF5 expression is high during embryonic development and decreased after birth. In response to in vivo and in vitro vascular injury [57] [58] [59] [60] [61] , and in atherosclerotic lesions [57, 58] , KLF5 is reinduced. In addition, more evidence indicates that KLF5 plays a potential proatherogenic role by activating its targets, i.e., PDGF-A, cyclin D1, cyclin B, Egr-1, VEGF and PAI-1 and subsequently promoting SMC proliferation, migration, apoptosis and vascular inflammation [57] [58] [59] [62] [63] [64] [65] [66] . While KLF5 is predicted to be proatherogenic, all the data collected are from in vitro experiment, in heterozygotes mice and in KLF5 transgenic mice given lethality of conventional KLF5 null mice prior to embryonic day 8.5 [57] [58] [59] [60] [61] [62] [63] [64] [65] 67] . Hence, it will be of great interest to generate a SMC-specific KLF5 mouse line and subject it to atherosclerosis studies.
KLF15
KLF15 is a crucial regulator of vascular SMC function. In contrast to KLF4 and KLF5, KLF15 expression is not detectable during early phase of development, increased after second half of gestation (Jain Lab, unpublished) and maintained till adulthood [68] . KLF15 expression in the vessel wall is largely in SMC [68] . Vascular KLF15 mRNA expression is significantly decreased by pathogenic stimuli, i.e., PDGF-BB, Angiotensin II and vascular injury both in rodent and in human vascular disease models [68, 69] . Systematic KLF15-deficiency promoted the development of restenosis and aortic aneurysm formation [68, 69] . Mechanistic studies suggest that KLF15-deficiency increases SMC proliferation, migration [68] and cell death [69] , enhances p53 function, decreases angiogenesis in vasa vasorum and promote vascular inflammation [69] . In light of these observations, one would predict that deficiency of SMC KLF15 should increase atherogenesis but these studies have yet to be reported.
Monocytes/Macrophages
Monocytes/macrophages play a pivotal role in the pathogenesis of a broad spectrum of inflammatory diseases, including atherosclerosis [70] . Endothelial cell injury is followed by monocytes adherence and migration into vascular wall, and differentiation to activated macrophages and foam cells that substantially contribute to vessel inflammation and disease progression. Not surprisingly, this cellular subtype was intensely targeted by many research studies in an effort to understand their complex role in plaque development. This critical role is evident by the halted atherosclerosis formation after monocytes/macrophages depletion or manipulation of cytokinemediated recruitment of these cells [71, 72] .
To date, 5 members of the KLF family have been implicated in the regulation of monocyte/macrophage biology. These include KLF1, KLF2, KLF3, KLF4, and KLF10. The most cogent evidence to date points to essential roles for KLF2 and KLF4 in monocytes differentiation, macrophage activation and polarization, and regulation of inflammatory signaling. We review KLF2 and KLF4 first followed by a brief discussion of the other KLFs.
KLF2
Kruppel-like factor 2 is a potent tonic repressor of monocyte/macrophage inflammatory activation. Interest in this factor was fostered by the observation that myeloid KLF2 levels were significantly reduced in human subjects with acute (sepsis) and chronic (atherosclerosis) inflammatory disease states [73, 74•] . Furthermore, in vitro gain and loss-of-function studies suggested that KLF2 inhibited macrophage pro-inflammatory activation. Specifically, overexpression of KLF2 attenuated LPS-mediated inflammatory cytokines production [73] while KLF2 depleted or deficient macrophages showed an anti-parallel effect [74•] . In vivo studies have confirmed the idea that KLF2 governs macrophage activation in models of acute and chronic inflammation. For example, reconstitution of immunodeficient animals with KLF2 overexpressing macrophages resulted in reduced inflammatory reaction in the carrageenaninduced paw inflammation model [73] . Further, animals with hemizygous deficiency of KLF2 exhibited more severe atherosclerosis [75] . Importantly, KLF2 -/+ macrophages demonstrated an increase in oxidized LDL uptake, while adenovirus overexpression of KLF-2 strongly inhibited lipid uptake by regulating the lipid binding protein FABP4 [75] .
Finally, and perhaps most convincingly, animals bearing myeloid specific deletion of KLF2 exhibited elevated baseline plasma levels of proinflammatory molecules (such as IL1b, IL12, INFg, MIP1b, MIP1a, and TNFa) suggesting that deficiency of KLF2 resulted in spontaneous myeloid activation. Since myeloid activation is important in the host response to bacterial infection, it was not surprising that these animals exhibited a robust capacity to combat polymicrobial infections [74•] . Collectively, these observations identify KLF2 as an essential regulator of macrophage inflammation.
Efforts to understand the mechanistic basis for KLF2 action reveal that this factor regulates two ancient stress pathways central to activation of the innate immune system in the setting of inflammation and hypoxia, namely NFκB and HIF-1α. Observations over the past decade have determined that HIF-1α is essential for macrophage activation. This is best highlighted by loss-of-function studies revealing that HIF-1α deficient myeloid cells exhibit reduced glycolysis/ATP production, a profound impairment of cellular motility, invasiveness, bacterial killing, and the response to sepsis [76] [77] [78] . More recently, studies from the Karin laboratory have shown that NFκB activity is required for HIF-1 protein accumulation in hypoxic cells and tissues. Given the central importance of the NFkB-HIF axis in macrophage activation, we sought to determine if KLF2 affected this molecular module. Indeed, we found that KLF2 potently inhibited NFkB transcriptional activity and consequently HIF-1 accumulation. Further, we showed that KLF2 did not affect nuclear accumulation or DNA-binding of NFkB. Rather, KLF2 inhibited the recruitment of key co-activators requisite for optimal NFkB activity such as CBP/p300 and CBP-associated factor (PCAF) [73] . Therefore, KLF-2 regulates the NFkB/HIF-1a axis that is central to macrophage pro-inflammatory activation [74•, 79] . These observations have important implications for atherogenesis. Plaque hypoxia is present in both human and murine atherosclerotic lesions, and is shown to promote local inflammation and angiogenesis thus increasing disease burden [80] [81] [82] .
The fact that hypoxia downregulates KLF2 [74•] may lead to NFkB/HIF-1 activation and accelerate vascular disease. Indeed, a recent study from Lingral laboratory provided an assertive evidence for the role of specific myeloid KLF-2 deletion in augmentation of atherosclerosis [83••] .
KLF4
KLF4 regulates both monopoiesis and macrophage subset specification. Initial studies showed that KLF4 was expressed in hematopoietic stem cells [HSCs] and that expression was induced as one progressed to the mature monocyte stage. Sustained expression of KLF4 in hematopoietic precursors induced monopoiesis while deficiency exhibited an anti-parallel effect [84] . Additionally, elegant studies by the Civin laboratory using fetal liver chimeric approaches defined an essential role for KLF4 in monocyte subset development [85] . Specifically, it was shown that KLF4 was required for both Ly6Chi and Ly6Clo monocyte populations. Collectively, these initial insights strongly supported a major role for KLF4 in monopoiesis. [84, 85] .
However, the importance of myeloid KLF4 in the mature macrophages in adult biology was unknown. Recent work from our laboratory sought to address this issue and identified KLF4 as an essential regulator of macrophage polarization [55••] . We note that cells of the monocyte/macrophages lineage exhibit remarkable plasticity that allows them to modulate their phenotype and efficiently respond to environmental signals and change their phenotype. For purposes of simplicity, a model system that classifies inflammatory macrophages as M1 and anti-inflammatory macrophages as M2 macrophages has been developed. M1 or classically activated (by LPS or INF-g) macrophages represent pro-inflammatory and are critical for host defense. However, excess activation can contribute to chronic inflammatory conditions such as insulin resistance and atherosclerosis. In contrast, M2 or the alternatively activated (by IL4 or IL13) macrophages are associated with tissue repair and resolution of inflammation. They have also been implicated in the plaque regression [86] . We showed that KLF4 levels were induced by M2 stimuli and reduced by M1 stimuli. In vitro gain and loss-of-function studies suggested that KLF4 promotes the M2 state while inhibiting the M1 phenotype, findings that were recapitulated in human inflammatory states such as diabetes. Experimentally, KLF4 null macrophages exhibited enhanced bactericidal effects, and animals with myeloid-specific deletion of KLF4 exhibited delayed wound healing, increased insulin resistance, and diet-induced obesity; all in concordance with the induction of M1 and lack of M2 phenotypes. Furthermore, studies in adipose tissue and stromal vascular fraction from human subjects showed decreased KLF4 expression in tissues from obese patients and a positive correlation of KLF4 level with Adiponectin (ADPN) and M2 markers (CD206, CCL18). Mechanistically, KLF4 was found to cooperate with STAT6 to promote quintessential M2 targets. On the other hand, inhibition of the M1 phenotype was achieved by inhibiting NFkB transcriptional activity via sequestration of its critical coactivators such as p300 and PCAF [55••] .
Other KLFs
Other KLFs such as KLF1, KLF3, and KLF10, are expressed in myeloid cells and implicated in modulation of IL12 p40 (a pro-inflammatory cytokine), hematopoietic differentiation, and bone marrow cell-induced neovascularization [13, 87, 88] ; and may therefore play a role in macrophage-induced vascular inflammation and development of atherosclerosis.
Lymphocytes
The importance of immune cells in atherosclerosis progression has been extended to include, not innate immunity only, but also adaptive immunity. Indeed, studies revealed the critical contribution of lymphocytes in intimal-adventitial crosstalk and disease development [89] . KLFs influence multiple processes in lymphocyte biology including lymphocyte quiescence, trafficking, differentiation and function. While the mechanisms behind the function of KLFs are currently being studied, KLF 2, 3, 4, 10 and 13 have been implicated in inflammatory processes with obvious implications for vascular disease.
KLF2
Naïve T cells are necessary to survey potential pathogens in blood and secondary lymphoid tissues. Once T cells are activated, they proliferate, acquire effector function, and home to areas inflammation. KLF2 expression is tightly coupled to T cell activation and regulates T cell migration, suggesting that this transcription factor may play an important role in the adaptive immune response. KLF2 is expressed in singlepositive (SP) CD4+ and CD8+ T cells residing in the thymic medulla, splenic white pulp and peripheral lymphoid tissues [90] . The transcription factor is maintained in T cells until they are activated by the T cell receptor. KLF2 maintains cell quiescence via inhibition of c-Myc expression and induction of p21Cip/Waf1. Mature, single-positive (SP) CD4+ and CD8 + T cells require KLF2 for trafficking and migration by promoting expression of sphingosine 1-phosphate receptor 1 (S1PR1) [91, 92] . S1PR1 recognizes high levels of sphingosine 1-phosphate in blood and lymph resulting in egress of T cells from the thymus and peripheral lymphoid tissues. T cell activation and rapid degradation of KLF2 [93] results in attenuated S1PR1 expression and retention of stimulated T cells in lymphoid tissues. Thymocytes deficient in KLF2 have attenuated expression of surface receptors (S1PR1, L-selectin, CCR7, and integrin β7) required for peripheral trafficking and migration [94] . Alternatively, KLF2 -/-T cells express proinflammatory chemokine receptors found on memory cells [90] and activated thymocytes including CXCR3, CCR3, CCR5 and CD69 [95] . These chemokines may be responsible for the altered homing patterns of naïve T cells to nonlymphoid tissues. Naïve T cells deficient in KLF2 accumulate in peripheral nonlymphoid tissues with fewer cells in secondary lymphoid tissues [95] . Thus, KLF2 regulates T cell homeostasis to restrict chemokine receptor expression and T cell movement to nonlymphoid tissues before T cell activation. Aberrant naïve T cell circulation may result in an immune compromised state via delayed antigen recognition or may result in autoimmunity by exposure to self-antigens.
Sen-Banerjee and colleagues showed that statin can enhance KLF2 expression in endothelial cells, a response associated with an anti-inflammatory phenotype [96] . More recently, these agents have been shown to increase KLF2 expression in T cells. Specifically, statins were found to attenuate T cell proliferation and IFN-γ expression in a KLF2-dependent manner. In a mouse-model of myocarditis mediated by heart-antigen specific CD8+ T cells, retroviral KLF2 overexpression and statin treatment resulted in an anti-inflammatory phenotype with attenuation of T-cell proliferation and interferon-γ (IFN-γ) expression [97] . The immunodulatory effect of statins mediated by KLF2 expression suggests that this pathway may be an important therapeutic target for cardiovascular disease.
KLF3
KLF3 regulates B cell quiescence, marginal zone B cell differentiation, trafficking and migration of B cells. KLF3 is rapidly downregulated upon activation of B cells, suggesting a role for KLF3 in B cell quiescence. The immortalized pre-B cell line 18-81, transformed by the proviral integration of Abelson-murine leukemia virus into the promoter region of the KLF3 locus, results in increased expression of KLF3 [98] . Premature somatic hypermutation and immunoglobulin class switching, in the 18-81 cell line, suggests a role for KLF3 in B cell activation and tumorigenesis. Retroviral integration in the KLF3 locus is associated with the development of B cell lymphomas, including follicular and marginal-zone non-Hodgkin's lymphomas [99] .
Moreover, KLF3 expression is attenuated in the absence of KLF2 suggesting that KLF2 may promote expression of KLF3. The balanced expression of KLF2 and KLF3 influences B cell differentiation. While KLF2 promotes the development of follicular B cells, KLF3 promotes MZ B cell differentiation. Also, while further investigation is necessary, some reports suggest that BCR signaling strength may further influence the differentiation of B cells [100] .
KLF3 may be responsible for innate and humoral responses. Vu et al have shown that CD 19+ splenic B cells of KLF 3 -/-mice have defects in TLR signaling pathway with significant downregulation of multiple TLRs and their coreceptor molecules. KLF3 deficient marginal B cells have an attenuated LPS response, mediated by the downregulation of Tlr6 and CD36. In addition to an impaired LPS response in KLF3 null MZ B cells, defective BCR signaling suggests compromised innate and humoral immunity, leading to increased susceptibility to infection [100] .
KLF4
KLF4 is expressed in early-stage B cell precursors through B cell maturation to promote proliferation and cell cycle arrest. KLF4 activates cyclin D2 expression by binding to the cyclin D2 promoter resulting in B cell receptor (BCR) -mediated B cell proliferation. Cells deficient in KLF4, and therefore cyclin D2, exhibit delayed entry in the cell cycle following BCR activation. Conversely, KLF4 overexpression in B cells transformed by the ABL oncogene induces cell cycle arrest. Expression of p21Cip/Waf1 and downregulation of c-Myc and cyclin D2 are believed responsible for the anti-proliferative effect of KLF4. Like KLF2 in T cells, KLF4 is rapidly degraded upon B cell activation. The differential effect of KLF4 on B cell proliferation is complex and poorly understood. Genotypic differences or the influence of cell-cycle regulators or cytokines may be responsible.
KLF4 promotes IL-17 expression and differentiation of Th17 cells, a subset of CD4+ T cells, known to mediate inflammation and tissue injury in autoimmune disease, such as multiple sclerosis and psoriasis, and anti-microbial immunity of epithelial and mucosal surfaces [101] . KLF 4-/-mice have decreased cellularity and reduced T-cell numbers in spleen partly due to attenuation of double negative thymocyte proliferation with resultant deficiency of Th17 cells [102] . Also, KLF4 directly promotes expression of the proinflammatory cytokine IL-17 by binding to its promoter; this action is independent of RORγt. The pathogenesis of autoimmune encephalomyelitis (EAE) has been attributed to IL-17 and Th17 cells, as mice deficient in IL-17 do not develop EAE when provoked with myelin oligodendrocyte glycoprotein [103] . Mice deficient in KLF4 show significant reduction in the severity of EAE characterized by reduced Th17 responses and infiltration of leukocytes into the central nervous system [102] .
KLF10
Cao et al have shown that KLF10 regulates CD4 + CD25-T cell activation [104] , T regulatory cell differentiation and Treg cell suppressor function. KLF10 promotes TGFβ1 and Foxp3 expression in CD4 + CD25-T cells. Treg cells deficient in KLF10 have reduced suppressor function due to decreased expression of TGFβ1, a consequence that is rescued by exogenous TGFβ1. Adoptive transfer of KLF10 -/-CD4 + CD25-T cells in ApoE-/-/scid/scid mice accelerated atherosclerosis. Atherosclerotic lesions were characterized by accumulation of T cells and macrophages in lesions with subsequent release of proinflammatory cytokines, chemokines and metalloproteinases.
KLF13
Expression of KLF13 protein primarily occurs during late stages of T cell activation and is responsible for induction of RANTES and regulation of T cell apoptosis. Phosphorylation of KLF13 by transcriptional co-activators promotes expression of the proinflammatory chemokine, RANTES to promote T cell activation. Mice deficient in KLF13 no longer inhibit expression of the anti-apoptotic factor BCL-XL and have enlarged thymuses and spleens containing preserved thymocytes [9•] . Thus, KLF13 may play a dual role in inflammation by recruitment of leukocytes followed by attenuation of the inflammatory response via apoptosis [105] .
Therapeutic Targeting of KLFs
There have been many efforts to therapeutically target KLFs giving their established role in regulating essential physiologic and pathologic processes. The anti-inflammatory 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are indeed shown to induce expression of KLF 2 and 4. In endothelial cells, statins induced KLF2 expression, and the induction of eNOS and thrombomodulin by statins was KLF2-dependent [96] . Similarly, statins induced expression of KLF2 in macrophages and lymphocyte resulting in an attenuated inflammatory response [97, 106] . Furthermore, resveratrol may exert its anti-inflammatory properties by the induction of KLF4 expression via a MEK5/MEF2-dependent signaling pathway in ECs [29, 107] . And a recent exciting discovery in cancer biology, trifluoperazine hydrochloride, a known anti-emetic and anti-psychotic drug, was shown to modulate the tumor suppresser FOXO/KLF6 transcriptional network resulting in enhanced tumor sensitivity to anti-cancer therapy [108] .
Future Direction
The indolent and progressive nature of atherosclerosis and the increasingly appreciated imbalance in pro and antiinflammatory forces highlight disease complexity and require additional rigorous efforts to better understand and dissect critical pathways that could alter disease course. Kruppel-like factors have emerged as essential transcriptional regulators of mammalians development and homeostasis. While additional studies are needed, the fact that they regulate the function of vascular and hematopoietic cells strongly suggests an important role in vascular inflammation. Therefore, pharmacologic targeting of KLFs will likely be impactful.
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